<DOC>
	<DOCNO>NCT03098225</DOCNO>
	<brief_summary>Graves ' orbitopathy ( GO ) disfigure disable disease profoundly impair quality life affect patient . High dose intravenous ( iv ) glucocorticoid ( GC ) ( ivGC ) well establish , widely use treatment active GO . The use systemic glucocorticoid take advantage immune suppressive antiinflammatory action , result overall beneficial effect range ~35 ~60 % patient various study . The intravenous route administration show superior oral route , term GO outcome side effect profile . The combination ivGC orbital radiotherapy ( OR ) use routinely patient moderate-severe , active GO , second-line treatment , also recommend recent Guidelines publish European Thyroid Association/European Group Graves ' Orbitopathy . Thus , majority study show OR increase response rate GC . Those study perform use oral GC , whereas know whether OR potentiate also effect ivGC . The present study aim determine whether OR potentiate effect ivGC treatment moderately severe active GO , term GO outcome quality life . A possible extension study foreseen , aim investigate long time GO outcome .</brief_summary>
	<brief_title>A Trial Evaluate Efficacy Orbital Radiotherapy Graves ' Orbitopathy</brief_title>
	<detailed_description />
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>1 . A diagnosis Graves ' disease base presence hyperthyroidism ( either untreated treated antithyroid drug ) associate detectable antiTSH receptor autoantibodies 2 . No major treatment hyperthyroidism ( thyroidectomy radioiodine ) last 3 month 3 . Euthyroidism antithyroid medication L'thyroxine ( LT4 ) since least 2 month 4 . GO symptoms last since one year 5 . Active GO : CAS ≥ 3 7 ( bad eye ) 6 . Moderate moderately severe GO : least one follow sign ( bad eye ) : Exophthalmos ≥ 22 mm Eye muscle involvement monoocular ductions direction gaze le 30° evident dismotility Diplopia accord Gorman score grade ac 7 . No corticosteroids immunosuppressive treatment GO last 3 month 8 . No contraindication OR : diabetes , hypertension , retinopathy type , glaucoma 9 . Male female patient age : 3575 year 10 . Effective method contraception whole trial least six week last intake trial drug ( female reproduce age ) 11 . No mental illness prevent patient comprehensive , write informed consent 12 . Compliant patient , regular followup possible 1 . Absence Graves ' hyperthyroidism ( present past ) 2 . Thyroidectomy radioiodine last 3 month 3 . Uncontrolled hyperthyroidism hypothyroidism 4 . GO symptoms last since one year 5 . CAS &lt; 3 ( bad eye ) 6 . Optic neuropathy 7 . Contraindications OR ( diabetes , retinopathy kind ) 8 . Pregnancy , breastfeed woman 9 . No informed consent 10 . Acute chronic liver disease 11 . Relevant Malignancy 12 . Chronic renal failure diseases relevance prevent steroid treatment 13 ) Corticosteroids immunosuppressive agent within last 3 month 13 . Recent ( ≤1 year ) history alcoholism drug abuse 14 . Previous orbital disease GO , eye injury surgery</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>